PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of...

Full description

Saved in:
Bibliographic Details
Main Authors MACHACEK, Michelle, REUTERSHAN, Michael, SLOMAN, David, SCHNEIDER, Sebastian, KAWAMURA, Shuhei, GIBEAU, Craig, WITTER, David, ALTMAN, Michael, YEUNG, Charles, SILIPHAIVANH, Phieng
Format Patent
LanguageEnglish
French
Published 24.06.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a compound of Formula (I) (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations. La présente invention concerne un composé de formule (I) (I) et ses sels, esters et promédicaments pharmaceutiquement acceptables, qui sont des inhibiteurs de PRMT5. L'invention concerne également des procédés de production de composés de formule I, des compositions pharmaceutiques comprenant des composés de formule I, et des procédés d'utilisation de ces composés pour traiter le cancer, la drépanocytose et les mutations de persistance héréditaire de l'hémoglobine fœtale (PHHF).
Bibliography:Application Number: WO2020US64759